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Immune responses to the gonococcus after natural infection ordinarily result in little
immunity to reinfection, due to antigenic variation of the gonococcus, and redirection or
suppression of immune responses. Brinton and colleagues demonstrated that parenteral
immunization of male human volunteers with a puriﬁed pilus vaccine gave partial protection
against infection by the homologous strain. However, the vaccine failed in a clinical trial.
Recent vaccine development efforts have focused on the female mouse model of genital
gonococcal infection. Here we discuss the state of the ﬁeld, including our unpublished data
regarding efﬁcacy in the mouse model of either viral replicon particle (VRP) vaccines, or
outermembrane vesicle (OMV) vaccines.TheOMVvaccines failed, despite excellent serum
andmucosal antibody responses. Protection after a regimen consisting of a PorB-VRPprime
plus recombinant PorB boost was correlated with apparent Th1, but not with antibody,
responses. Protection probably was due to powerful adjuvant effects of the VRP vector.
New tools including novel transgenic mice expressing human genes required for gonococ-
cal infection should enable future research. Surrogates for immunity are needed. Increasing
antimicrobial resistance trends among gonococci makes development of a vaccine more
urgent.
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INTRODUCTION: NEED FOR A VACCINE FOR GONORRHEA
Neisseria gonorrhoeae (the gonococcus, or GC) remains an impor-
tant disease. Still relatively common in the US, with over 300,000
reported cases annually, and probably as many that are not
reported, it is much more common in Africa and in many other
parts of the less-developed world. Untreated gonococcal infection
in women may progress to pelvic inﬂammatory disease, increas-
ing the risk of ectopic pregnancy and infertility. Calculations of
attributable risk show that GC is one of the signiﬁcant cofactors
for HIV transmission (Fleming and Wasserheit, 1999), increasing
risks of HIV transmission and acquisition about threefold. These
factors alone should promote interest in a vaccine for this ancient
disease.
Another reason to urge development of a gonococcal vaccine is
emergence of antibiotic resistant GC. In many parts of the world,
ﬂuorinated quinolones are no longer recommended because of the
prevalence of resistance (Newman et al., 2007; Schultz et al., 2001;
Lewis, 2010). Resistance to cephalosporins also is emerging, ren-
dering oral formulations such as ceﬁxime less effective (Lo et al.,
2008; Golparian et al., 2010; Lewis, 2010). A steady creep toward
decreased in vitro susceptibility to ceftriaxone in SE Asia and else-
where (Chisholm et al., 2010) will threaten utility of ceftriaxone,
the principal remaining parenteral therapy for GC, if the trend
continues. Current U.S. gonorrhea treatment guidelines increased
the dose of parenteral ceftriaxone from 125 to 250mg to attempt
to counteract the slow increases in cephalosporin resistance (Cen-
ters for Disease Control, 2010). Resistance to quinolones and beta
lactams is due to chromosomal mutations, including alterations
of the target sites for these antimicrobials, and also alterations
of porin entry channels and/or efﬂux pumps (reviewed in Lewis,
2010). Most of the resistant mutants appear to be ﬁt, in the sense
that they persist and spread in the natural world.
Although plasmid-mediated resistance to penicillins and tetra-
cyclines has leveled off (Lewis, 2010), history teaches that contin-
ued selection of more resistantGC variants is to be expected, either
by additional chromosomal mutations or acquisition of plasmids.
We expect that in a decade, GC resistance to antimicrobials will
increase, and therapy with existing cephalosporins will no longer
be useful. There are few if any promising new antimicrobials for
GC on the horizon. It takes at least a decade or more to create
vaccines. Now is the time to be serious about the problem.
The increasing threat of difﬁcult-to-treat GC should make
a gonococcal vaccine an important objective, but there is rela-
tively little work at present on such a vaccine. A PubMed search
on 12.27/2010 under “gonococcal vaccine” yielded 247 entries,
whereas a similar search under “meningococcal vaccine” yielded
3326 entries. The reasons for this glaring discrepancy are not obvi-
ous, but may include such commercial factors as estimated market
size for vaccines, the probability that the public would accept and
utilize the vaccine, and who would pay for the vaccine. It is possi-
ble that the shock of witnessing meningococcal (MC) disease and
death in innocent infants and young adults helps to energize the
MC vaccine programs. By contrast, GC disease is a silent killer of
the unborn, due to salpingitis and ectopic pregnancy. Some might
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view GC as just a minor infection, and one that is acquired by
personal choice. If it can be treated, why bother with a vaccine?
Another obvious consideration is the likelihood that a vaccine can
be developed, based solely on the available science. In the absence
of evidence for naturally acquired immunity after infection, and
correlates for protective immunity, it is difﬁcult for commercial
operations to push forward with vaccine development. The result
has been discontinuance of the former US military GC vaccine
program, and in termination of related programs in virtually every
large-scale manufacturers of vaccines in the US and Europe.
In this review, we examine the natural history of infection
with emphasis on immune response and immunity to infection,
and certain new evidence regarding the pathogenesis of infec-
tion.Other comprehensive reviews of GCpathogenesis and animal
models are included elsewhere in this volume. Previous reviews of
gonococcal vaccines covered pathogenesis and antigens that might
be used for a vaccine (Blake and Wetzler, 1995; Sparling et al.,
2003; Edwards and Apicella, 2004; Virji, 2009). We discuss previ-
ous vaccine attempts, as well as lessons learned from vaccines for
comparable diseases, especially the close sibling of GC, the MC.
We then present previously unpublished experiments from our
laboratories, which were “negative” in the sense that they did not
show evidence for protection in the female mouse model of gen-
ital GC infection. Nevertheless, they inform future investigations,
and one surprising result in particular suggests a path forward for
additional research.
IS THERE EVIDENCE FOR NATURALLY ACQUIRED IMMUNITY
TO REINFECTION?
In the preantibiotic era, symptomatic infections resolved sponta-
neously over months, although the basis for apparent immune
resolution was not studied (Hill, 1942). In the current era of
readily available antibiotics, persons commonly acquire gonor-
rhea, are treated, but are soon reinfected. Mild or asymptomatic
infection may be carried for months without treatment, both in
men and women (Handsﬁeld et al., 1974). A community outbreak
due to a highly resistant strain demonstrated that reinfections with
the same strain were common after treatment of uncomplicated
genital infection (Faruki et al., 1985). There was no evidence for
increased resistance to a second infection in studies of experimen-
tal GC of male human volunteers, even when the repeat infection
was initiated only 2weeks after treatment of the ﬁrst infection by
the same MS11 gonococcal strain (Schmidt et al., 2001) The infec-
tions of experimental subjects had to be terminated at onset of
symptoms for ethical reasons, undoubtedly before a full immune
response was initiated.
A study of highly experienced female commercial sex work-
ers in Africa showed apparent immunity to recurrent infection;
protection was speciﬁc to particular outer membrane porin pro-
tein B (PorB) serovars, and was not generally protective against
other strains (Plummer et al., 1989). However, a similar study
in a small US community, involving men and women, who cer-
tainly had fewer previous episodes of GC than the African female
cohort, actually found an increased rate of reinfection by the
same PorB serovar (Fox et al., 1999). Increased rates of second
infections by the same strain could have been due to the greater
likelihood of sexual reexposure to still-infected partners. Other
data from this same study showed there was some antigenic varia-
tion in exposed PorB surface loops during repeated passage of this
strain through the community (Hobbs et al., 1999). A small study
claimed PorB serovar speciﬁc immunity to reinfection in women
who had salpingitis (Buchanan et al., 1980). Conceivably, repeated
infections elicited immune memory responses, providing the basis
for protective immunity on reexposure.
A somewhat more optimistic view of immunity after local
mucosal infection was provided by studies of experimental GC
in chimpanzees. Certain GC strains were capable of infecting the
chimp urethra, pharynx, and cervix; the infectious dose was high
for the pharynx and cervix, but for the male urethra the required
inoculum was about 1× 104 colony forming units (CFU), essen-
tially the same as for human urethral infection (Kraus et al., 1975).
Infectionpersisted forweeks,but then anuncharacterized immune
response cleared infection, as deﬁned by two successive nega-
tive cultures. Initiation of a second infection by the same strain
1week after termination of ﬁrst infection required an infectious
inoculum about 1000-fold greater. Repeat challenge 2 years after
the ﬁrst infection showed that immunity had completely waned
(Kraus et al., 1975). These experiments also showed that bacte-
ricidal serum antibodies protected against urethral infection in
the chimp: the only GC capable of infection were of the PorB1B
serovar class, which were able to bind chimp complement four
binding protein (C4bp), rendering them phenotypically serum
resistant (Ngampasutadol et al., 2005). PorB1A strains were not
able to bind C4bp and were unable to infect at the highest inoc-
ula tested. Chimps are expensive, difﬁcult to work with, and are
now virtually unavailable for similar studies. That is unfortunate,
since they are the only non-human primate capable of mucosal
infection by GC.
In sum, the evidence does not provide much support for nat-
urally acquired immunity, and outside of chimps, almost none
for immunity after uncomplicated infection. What evidence exists
suggests immunity is strain speciﬁc,which is not helpful in the clin-
ical arena. Regardless, failure of natural immunity after infection
can have many causes, and does not in itself prove that a vaccine is
not possible. A vaccine might induce a much greater and different
immune response than occurs after mucosal infection.
HUMAN IMMUNE RESPONSE TO GC
Uncomplicated mucosal GC in humans results in an immune
response, but in many studies the response was weak and brief.
Serum antibodies have been documented against many different
GC antigens (reviewed in Sparling et al., 2003). Men tend to have
a poorer response than women (Tapchaisri and Srinisinha, 1976;
Miettinen et al., 1989; Hedges et al., 1999). In almost all studies
detectable serum antibodies were gone within a few months, or
less. In cervical mucus, IgG antibodies were at least as prevalent
as IgA (Tapchaisri and Srinisinha, 1976). In keeping with an over-
all modest immune response to GC, Hedges et al. (1998) found
elevations only of lL-6 in serum of infected women; none of the
measured cytokines was elevated in cervical mucus. Only tran-
sient elevations of IL-1β, IL-6, IL-8, and TNFα in urine and serum
occurred in experimentally infected men (Ramsey et al., 1995).
Kasper et al. (1977) found bactericidal responses in about one-
third of uncomplicated infections, but in only 5% of women with
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salpingitis at the time of their presentation for care, suggesting that
bactericidal antibodies might protect against salpingitis. Conva-
lescent sera showed a fourfold rise in bactericidal titers in 70% of
women with severe salpingitis, as compared to only 11% with mild
disease (Kasper et al., 1977). Bactericidal antibodies were common
in patients with mucosal infection, but did not prevent infection
(Brooks and Ingwer, 1978).
Hedges et al. (1999) provided the best study in many ways
of immune responses in uncomplicated GC infection of men
and women. Sera and genital secretions were tested by ELISA
for isotype-speciﬁc responses to whole formaldehyde-ﬁxed GC
strains, both their own infecting strain, and a standard MS11
strain. Strain-speciﬁc IgA1 but not IgA2 antibodies were observed
in both serum and cervical mucus in some subjects. A weak sec-
ondary IgG response was seen in some individuals. Women had
greater responses than men, but responses were brief and tem-
porary, declining within weeks of treatment. Previous infection
did not result in immunological memory; titers and duration of
antibody responses were identical in ﬁrst infections and in those
with previous infections. The authors’ suggested that GC might
somehow suppress the immune response of the host, although no
mechanism was offered.
The concept of immune suppression or redirection by com-
mensal and pathogenic bacteria is now a very active area of
research. There is evidence that GC are able to suppress either
human CD4 T cell responses (Boulton and Gray-Owen, 2002;
Lee et al., 2008) or human B cell antibody responses (Pantelic
et al., 2005) in vitro. These effects of GC on human immune
cells are regulated by binding of GC opacity (Opa) proteins to
human carcinoembryonic antigen cellular adhesion molecule 1
(CEACAM1) on lymphocytes (Boulton and Gray-Owen, 2002;
Pantelic et al., 2005). Binding CEACAM1 initiates a broad-range
of inhibitory effects on T cells (Nagashi et al., 2008). In mice,
GC infection stimulates a Th-17 response, with inﬂux of mucosal
polymorphonuclear leukocytes (PMNs; Feinen et al., 2010). This
apparently is beneﬁcial, since GC are able to substantially resist
PMN-mediated killing (Simons et al., 2005, 2006;Criss and Seifert,
2008; Criss et al., 2009). From the view of a vaccine develop-
ment, evidence that GC suppresses or redirects immune responses
is good news, since it opens the possibility that a vaccine might
circumvent such immune manipulation by GC.
The most promising approach has been to examine targets for
biologically relevant immune responses. Much work has focused
on a complex of three antigens that cluster together in the outer
membrane (OM): lipooligosaccharide (LOS); Reduction modiﬁ-
able protein (RMP), formerly designated PIII; and porin protein
(PorB). The structures and biology of these molecules have been
reviewedmany times (Sparling et al.,2003;Virji,2009). LOSunder-
goes frequent phase variation in the structure of its polysaccharide
side chains, and also can be sialylated, rendering strains more
serum bactericidal resistant but less invasive. Sialylated LOS also
partiallymasks adjacent PorB trimers in theOM, reducing binding
of monoclonal antibodies (mAbs) to PorB by about 50% (Elkins
et al., 1992). RMP is a potent immunogen and elicits blocking
antibodies that subvert the killing effects of bactericidal antibodies
directed against PorB or LOS (Blake et al., 1989). PorB exists in two
main classes, designated PorB1A and PorB1B, each the product of
the porB gene. The PorB1A and PorB1B classes vary in certain
domains of the eight exposed loops that project out from the OM,
and within each class there are many minor variants that differ in
sequence and antigenicity (serovars). PorB is the major protein in
the outer membrane, and is essential; porB knockouts are lethal.
PorB is crucial for entry of low molecular weight anions, and is
involved with Pil and LOS in cooperative binding to complement
receptor 3 (CR3) in primary cervical cells (Edwards et al., 2002).
PorB also is capable of penetrating epithelial cells, facilitating inva-
sion (Weel andPutten,1991; see also reviews byMassari et al., 2003;
Sparling et al., 2003; Edwards and Apicella, 2004; Virji, 2009), and
leading to apoptosis, by means of entry into mitochondrial mem-
branes within the cell (Massari et al., 2003; Kozjak-Pavlovic et al.,
2009; Rudel et al., 2010). PorB does not undergo phase varia-
tion, unlike many important cell surface molecules involved in
GC pathogenesis including LOS, pili (Pil), and opacity proteins
(Opa). Thus, it is no surprise that PorB has evolved many mech-
anism for protection from host defenses, including binding the
complement regulatory proteins C4bp and factor H (fH; Ram
et al., 1998; Jarva et al., 2007; Madico et al., 2007; Lewis et al., 2008;
Ngampasutadol et al., 2008), in addition to the protections offered
by sialylation of LOS and the elicitation of blocking antibodies
by RMP.
The immediate importance to this discussion is evidence that
differences in immune responses to the RMP, LOS, and PorB triad
affects susceptibility to infection.Data presented in summary form
suggested that susceptibility to infection after sexual exposure to
an infected partner was determined by an equation: antibodies
against (PorB+ LOS)/antibodies against Rmp equals susceptibil-
ity; the higher the ratio, the lower the risk (Rice et al., 1974; Blake
andWetzler, 1995). Unfortunately, complete details of these exper-
iments have not been published, to our knowledge. Other efforts
for a vaccine based on PorB or certain LOS epitopes are dis-
cussed below. Avoidance of Rmp antigen is one goal of current
vaccine design.
GONOCOCCAL VACCINES FOR HUMANS
Only two vaccines for GC have entered into clinical trials. The ﬁrst
was a crude killed whole cell vaccine, which was studied in a con-
trolled experiment in a population of Inuit in northern Canada
with high incidence and prevalence of GC infection (Greenberg
et al., 1974; Greenberg, 1975). There was no evidence for protec-
tion, even though the vaccine was said to be well tolerated and
induced an antibody response in over 90% of vaccine recipients.
Since it was a crude whole cell vaccine, the alleged good tolerance,
with onlymild reactions,was surprising, since the vaccine certainly
contained highly inﬂammatory LOS. Similar efforts with MC vac-
cines have utilized either detergent delipidated OMs to remove
toxic lipidA,ormutants of LOS that no longer produce toxic forms
of lipid A (reviewed by Granoff, 2010). The whole cell GC vaccine
was not developed further.An analogous vaccinemade from a pili-
ated GC strain was tested in chimps by investigators from the CDC
in Atlanta, with good serum bactericidal and immunoﬂuorescent
antibody responses. This vaccine resulted in protection very simi-
lar to that observed after natural immune clearance of infection in
chimps, requiring a 1000-fold larger inoculum to infect vaccinated
animals (Arko et al., 1976).
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The most signiﬁcant effort focused on a puriﬁed Pil vaccine.
Pil are crucial for initial attachment to a variety of human cells.
Either the pilus ﬁbril, the product of the pilE gene, or a minor
pilus-associated protein designated PilC, or both, mediate attach-
ment to a still uncertain receptor. On primary cervical epithelial
cells, Pil mediate attachment to CR3 in conjunction with PorB
(Edwards et al., 2002; Edwards and Apicella, 2004). A series of ele-
gant experiments proved that isolated and puriﬁed Pil containing
an uncertain amount, but probably not much, of contaminating
PilC, was able to protect human volunteers from experimental
urethral infection after parenteral immunization (Brinton et al.,
1982). The vaccine elicited a broad antibody response in serum
and in genital secretions, including secretory IgA. Mucosal anti-
bodies blocked adherence in vitro of piliated GC to various cells
(McChesney et al., 1982). A subsequent trial that was never pub-
lished in detail showed no protection against a heterologous strain
expressing antigenically variant Pil (Tramont and Boslego, 1985).
Nevertheless, a large-scale ﬁled trial of the single-antigen Pil vac-
cine was carried out in high-risk US military personnel stationed
in Korea, using a smaller dose and a different route (intradermal)
than that used in the initial proof-of-principle experiment. The
result was not even a hint of protection (Boslego et al., 1991). The
probable reason for failure was antigenic variation of expressed Pil
in the naturally acquired infections (Criss et al., 2005). Since then,
there have been relatively small efforts to discover and develop a
common Pil epitope for use in a next-generation vaccine, but so
far, no useful data have been forthcoming.
Other vaccine candidates have been and are being considered,
as will be discussed below, but none has advanced to clinical trial.
WHAT CAN BE LEARNED FROM MENINGOCOCCAL
VACCINES?
An examination of the state of MC vaccines may be instructive.
Vaccines for MC disease traditionally used capsular polysaccha-
rides, which induced bactericidal responses that were protective
against invasive disease including bacteremia and meningitis.
These developments built upon classic studies that showed that
epidemic MC disease was the result of colonization of persons by
epidemic strains to which the subjects had no pre-existing bacte-
ricidal antibodies (Goldschneider et al., 1969a,b). Serum bacteri-
cidal antibody (SBA) titers of at least 1:4 were strongly correlated
with protection from disease, whether induced by naturally occur-
ring infections with bacteria that share similar capsular antigens
with encapsulated MC, or by the MC capsular antigen vaccines
(Frasch et al., 2009; Granoff, 2009). SBA is a better measure of
protection than ELISA titers against capsular antigen (Frasch et al.,
2009). SBA also is well correlated with protection from invasive
disease by several other encapsulated bacteria, including pneumo-
cocci and Hemophilus inﬂuenzae (Conference Report, 2010). A
variety of efﬁcacious capsular vaccines were developed, includ-
ing capsular polysaccharides conjugated to protein antigens to
increase immunogenicity in the young. Capsular vaccines against
serogroup C MC result in decreased carriage as well as protection
from invasive disease, yielding a signiﬁcant effect on transmission
within the community (Maiden et al., 2008). A conjugate vaccine
for groupAMCdesignated“MenAfriVac” is now being introduced
in the meningitis belt in Africa, under the aegis of a consortium
known as theMeningitisVaccine Project (Butler, 2010), and conju-
gate vaccines for other MC capsular types are now widely deployed
in practice.
MC disease differs from GC in two crucial respects: GC do not
make capsular polysaccharides, and GC only occasionally invade
the blood stream, typically restricting damage to the lower and
upper genital tracts. Thus, correlates for protection against MC
disease such as SBA may not predict correlates for protection
against GC. Moreover, SBA is not the only predictor of protec-
tion for MC disease; Granoff argues that the SBA level of at least
1:4 is sufﬁcient for protection, but is not a sensitive measure of
protection, since many are protected with lower levels of measur-
able SBA (Granoff, 2009). Opsonophagoyctic activity (OPA) with
human serum and PMNs appears to be a good predictor of efﬁcacy
for experimental group B MC vaccines (Granoff, 2009).
Progress in development of a vaccine for group B MC might
help inform development of a GC vaccine. Non-capsulate GC and
MC are not identical, but share many outer membrane proteins,
and their LOS are similar. For decades, serogroup B MC have been
an elusive target for a vaccine because the capsule of group B
MC is identical to human central nervous system (CNS) antigens,
causing fear of cross-reactive anti-CNS immune responses. For
this reason, all efforts for a group B MC vaccine are now focused
on non-capsular antigens. Detergent-extracted outer membrane
vesicles (OMV) appear to be safe, and have been used success-
fully to control local epidemics. The LPS also can be modiﬁed
genetically so as to express a lipid A bearing either four or ﬁve
acyl residues instead of the usual six, reducing the reactogenic-
ity of OMV vaccines signiﬁcantly (Donnelly et al., 2010; Keiser
et al., 2010).However, the immunodominantOMVproteinPorA is
antigenically variable (reviewed in Granoff, 2010). OMV vaccines
prepared from multiple PorA type strains have been tested and are
efﬁcacious, but are not highly immunogenic in infants (Granoff,
2010). (GC contain a porA pseudogene, but do not express PorA).
By a variety of methods including whole genome sequencing,
in silico predictions of which genes express novel outer mem-
brane proteins,proteomics, genetic engineering, and immunology,
a small set of candidate novel protein immunogens were selected
for further study. SBA served as the surrogate for protection, and
enabled more rapid development than would have been possi-
ble without such a reliable simple assay for protective immunity.
Progress required a large investment of resources by industry, the
FDAand academic laboratories. Twonewvaccines are in late stages
of clinical trials. In one, three protein immunogens, consisting of
two fusion proteins and a third single protein, are coupled with an
OMV vaccine expressing PorA (Keiser et al., 2010). The vaccine
appears to be more effective when the recombinant proteins are
coupled with OMV rather than being administered alone (Find-
low et al., 2010). The key novel proteins are NadA, an adhesin;
a heparin binding protein formerly designated 2132, now des-
ignated NHBP; and a protein that binds fH, designated fHbp
(Beerink and Granoff, 2008; Donnelly et al., 2010). Antibodies
against fHbp are directly bactericidal, and also prevent binding of
fH, further promoting bactericidal activity.All of these proteins are
widely expressed among MC strains, and are relatively conserved,
although fHbp exists in three major antigenically distinct families
(Beerink and Granoff, 2008; Donnelly et al., 2010). Clinical trials
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have been conducted in adults and infants, and results are suf-
ﬁciently promising to support large phase three trials, which are
underway (Findlow et al., 2010; Snape et al., 2010). Meanwhile,
others are investigating construction of additional novel immuno-
gens (Lewis et al., 2010), including OMV expressing hybrids of
the fHbp family that result in antibodies that cross react widely
against MC strains (Beerink and Granoff, 2008; Koeberling et al.,
2009). With any luck, we soon will witness the clinical deployment
of efﬁcacious vaccines in adults and infants for all MC strains, a
triumph.
What are the lessons for a gonococcal vaccine? Many of the
key protein antigens identiﬁed in MC are not present or are not
functional in GC. PorA is not expressed in GC. NadA is absent
from all of the sequenced GC genomes (Comanducci et al., 2002;
and unpublished observations). GC has a fHbp homologue but
it is not predicted to be localized to the surface as in MC, since
it lacks a functional signal sequence. Deletion of this gene does
not decrease factor H binding or alter serum resistance (Welsch
and Ram, 2008). NHBP is present in several of the sequenced GC
genomes and remains a viable target. Development of a vaccine
similar to the MC group B vaccine should be possible, but will
require a much larger effort than that currently underway. Use of
OMVs with engineered LOS structures that are less reactogenic
should be easy. OMVs can be constructed to express a variety of
antigens, including hybrid PorB. Reliance on a single protein anti-
gen is problematic. All the tools to do this are available, with one
major exception: there is no reliable surrogate such as the SBA to
guide development.
CHOICE OF THE MOUSE MODEL FOR DEVELOPMENT A
GC VACCINE
Development of the female genital tract mouse model for studies
of pathogenesis of GC (Jerse, 1999) opened up new possibilities
for early phase studies of possible vaccines for GC. Infection in
mice persists for about 2weeks after the initial inoculation, and
rates of decline can be used to measure resistance to infection.
Mixed infections also can be used to test relative ﬁtness of strains,
and presumably could be used to test relative abilities to resist spe-
ciﬁc immune responses to particular antigens. The most attractive
aspect of the mouse for vaccine development, apart from avail-
ability and cost, is the advanced state of development of mouse
genetics, and the superb tools for monitoring immune responses
in the mouse. Similar to observations in humans, mice develop
an inﬂammatory immune response, but no resistance to repeat
infection by the same strain, and no immune memory responses,
after genital tract infection (Song et al., 2008).
The mouse model has many deﬁciencies, including (at the time
our studies were performed, see below) lack of: receptors for bind-
ing Pil and Opa; human C4bp or fH; and iron binding proteins
other than hemoglobin and heme that can be used by GC for
growth. Each of these is a problem, and in aggregate, it is uncer-
tain howﬁndings in amouse can be translated to human infection.
Nevertheless, conﬁdence that the mouse model is relevant to stud-
ies of GC biology is enhanced because of the correlations in roles
of some virulence factors for both mice and humans. Sialyla-
tion of LOS appears to be requisite for maximal infectivity in
mice, just as in humans (Wu and Jerse, 2006). Surprisingly, Opa
expression is selected in themouse, even in the absence of theCEA-
CAM receptors for Opa (Cole et al., 2010). In humans, there also
is strong selection for Opa expression in male volunteers (Jerse
et al., 1994). Drug resistance efﬂux pumps involved in antibi-
otic resistance are required for maximal infectivity in the mouse,
apparently by means of exporting cationic innate immune defense
proteins (Warner et al., 2008). The mouse model, although imper-
fect, seemed the best choice for our efforts to investigate protective
immune responses, aiming to discover which antigens might be
useful in a vaccine, and correlates of protection.
But which antigens? Because of lack of their receptors, expres-
sion of phase-variable GC pili is not maintained in mice, making
study of Pil vaccines impossible.Moreover, themousemodel is not
particularly robust, making it very difﬁcult to utilize a shotgun of
antigens, either as genetic constructs or as proteins. We decided to
focus on intranasal (IN) vaccination with outer membrane prepa-
rations,because IN immunization results in strong genitalmucosal
responses, and because of the success of theMCOMVvaccines.We
also chose to closely examine a few outer membrane proteins. For
initial studies of immunogenicity, we included the GC transferrin
receptor protein TbpB, because it is an immunogenic lipoprotein,
and is essential for gonococcal infection of male humans using
strain FA1090 (Cornelissen et al., 1998; Cornelissen, 2008). The
other candidate selected was PorB, because it plays many essential
roles in infection, including binding to CR3 on female epithelial
genital cells in a complex with Pil and LOS (Edwards et al., 2002);
binding of PorB1A to Gp96 and SREC on epithelial cells, facilitat-
ing both adherence and invasion (Rechner et al., 2007); binding
of both C4bp and fH to discrete and different loops on either
PorB1A or PorB1B, enabling resistance to complement-mediated
killing (summarized above); and evidence that some polyclonal
and mAbs to PorB are bactericidal (Virji et al., 1986; Heckels et al.,
1989; Butt et al., 1990). Moreover, PorB is an adjuvant, through
binding to TLR2 (Wetzler, 2010).
OMV VACCINES NOT UNIFORMLY SUCCESSFUL IN MICE
Immunizationwith gonococcalOMV is an attractive vaccine strat-
egy due to the potential of OMV to elicit an immune response
against several different conformationally correct components
on the bacterial surface. There was reason to believe OMV vac-
cines were likely to be effective, by analogy to success with MC
OMV vaccines, and because of one report of a successful trial
of a GC OMV vaccine in the mouse model. Plante et al. (2000)
reported that IN immunization of female mice with gonococcal
OMV reduced colonization following vaginal challenge with the
homologous wild-type strain MS11. Signiﬁcant protection was
observed in the two experiments that were reported in this study,
and in an unreported experiment that was performed prior to
these experiments. However, no protection was observed in sim-
ilar experiments testing either MS 11or FA1090 OMV that were
performed subsequent to these published experiments. The OMV
preparations that showed protection were prepared by shaking
whole bacteria with glass beads for 2 h at 45˚C, whereas the failed
experiments used OMVs prepared by passing bacteria through a
needle. It is possible that differences in the preservation of confor-
mational epitopes might be responsible for inability to reproduce
these data. Additional differences in the experiments included a
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slightly higher dose of estradiol in the mice that did not show
protection by OMV vaccine.
Failure to reproduce the initial OMV vaccine results could have
been due to presence of Rmp in outer membranes from wild-type
MS11. Anti-Rmp blocking antibodies could have reduced effec-
tiveness of antibodies against either LOS or PorB. To test this,
we immunized mice with OMV isolated from an rmpA insertion
mutant of another PorB1B strain, strain FA1090, grown under
iron-restricted conditions so as to express iron-repressed proteins.
OMVswere prepared by passing bacteria through a small bore nee-
dle. Mice developed substantial anti-PorB serum IgG antibodies, a
rise in SBAs, vaginal PorB-speciﬁc IgG, and very high levels of vagi-
nal PorB-speciﬁc IgA antibodies (Zhu et al., 2005). Despite what
one might have assumed were the types of responses that would
correlate with protection, there was no protection after IN OMV
immunization (Table 1). We concluded that anti-Rmp blocking
antibodies were not responsible for the lack of effectiveness of
OMV vaccine antigens in vivo. These results also showed that
induction of mucosal IgG and IgA antibodies, and a bactericidal
serum response, did not predict protection.
Another reason for failure of the vaccines could be in vivo
sialylation of LOS, leading to resistance to mucosal antibodies
and complement. Increased resistance to complement-mediated
defenses in humans occurs via the covalent linkage of sialic acid to
LOS molecules with a lactose-N -tetraose moiety, which reduces
activation of the alternative pathway of complement activation
via the binding of fH. Although mouse fH does not bind to sia-
lylated LOS (Ngampasutadol et al., 2008), sialylation does reduce
opsonophagocytosis following incubation of GC in mouse serum,
and an lst mutant (which lacks sialyltransferase, and can not sia-
lylate LOS) was attenuated for murine infection (Wu and Jerse,
2006). To test the effect of sialylation in vivo on possible escape
from OMV-induced immune protection, we used wild-type F62
and an isogenic lst mutant as the challenge strains, after IN immu-
nization with F62 OMVs. Ovariectomized BALB/c mice were used
to circumvent the need for mice to be in anestrus or in the
diestrus stage of the estrous cycle during the challenge phase of the
experiment. High titers of OMV-speciﬁc serum IgG and vaginal
IgG and IgA were detected following immunization. Mice were
challenged 3weeks after the ﬁnal immunization. There was no
difference in the duration of recovery or number of wild-type
or lst mutant bacteria recovered (Figure 1). Similar results were
obtained after IN immunization with the strain MS11 OMVs,
followed by challenge with either MS11 or its isogenic MS11lst
mutant. We concluded that sialylation was not responsible for
gonococcal evasion of an OMV vaccine-induced host response in
the mouse model.
Thus, three different outer membrane vaccines delivered IN
resulted in high titers of serum antibodies, excellent serum bac-
tericidal activity, and robust mucosal responses as assessed by
analysis of vaginal wash and fecal pellet antibodies (Zhu et al.,
2005; and data not shown), yet were uniformly completely inef-
fective in either accelerating clearance or preventing GC infection
in the female mouse genital tract. OMV may still play some role
as a component of a GC vaccine, but we shifted our attention to
individual outer membrane protein antigens.
RECOMBINANT PROTEIN VACCINES
The ﬁrst consideration was how to prepare puriﬁed protein anti-
gens in a conformationally correct form, in sufﬁcient amounts,
and in the absence of contaminants that might be a problem,
including LOS and the blocking antigen Rmp. Problems due to
the blocking effects of antibodies to Rmp could be avoided by use
of cloned recombinant preparations of PorB. Considerable effort
by commercial partners went into preparing a refolded recombi-
nant FA1090 PorB1B (rrPorB) from E. coli, in a conformation
that closely mimicked that of native PorB extracted from GC
(Matsuka et al., 1998). A phase 1 human trial was undertaken,
but was not carried forward to test for protection of male volun-
teers, apparently because of problems with adverse rates of local
inﬂammation due to the vaccine. The rrPorB served as an excellent
immunogen for studies inmice. Preparing batches of themuch less
hydrophobic TbpB was less problematic (Thomas et al., 2006).
VRP AND DNA VACCINES
Another very attractive option was to use genetic vaccines express-
ing either PorB or TbpB. Such an approach would allow much
greater ﬂexibility in exploring combinations and variations in
the antigens. DNA vaccines have the advantage of great simplic-
ity. There has been a surge in interest in viral derivatives that
deliver antigens either as a viral like particle (VLP) that do not
replicate, or as viral replicon particles that have a single cycle
Table 1 | Immunization with OMV or rrPorB fails to protect female mice from genital infection by FA1090.
Vaccination regimen Route N Days infected (Mean±SD) p value
Mock-PBS Dorsal SQ 13 7.23±2.68
rmp OMV Intranasal 8 7.50±3.16 0.77
rrPorB Dorsal SQ 10 7.10±3.93 0.89
rrPorB Footpad 8 5.50±2.52 0.21
BALB/c mice were prepared in groups of 15 as described by Jerse (1999). Immunizations were conducted three times at intervals of 3weeks, using either 20μg
protein of an Rmp mutant of FA1090 OMV (rmp OMV) in 20μl of PBS; or 10μg protein of recombinant renatured PorB from FA1090 (rrPorB) prepared as described
by Matsuka et al. (1998) mixed 1:1 in 10μl PBS with Ribi-700 adjuvant, delivered either by the dorsal or footpad route. Three weeks after the last boost, mice in
diestrus phase were implanted with an estradiol pellet and treated with antibiotics to reduce the normal vaginal ﬂora (Jerse, 1999).Two days later they were inoculated
intravaginally with 1×106 CFU of FA1090, and followed with daily quantitative vaginal cultures. Days to last positive culture are shown. Log rank was used to compare
the results between the groups. A weak but repeatable trend was observed for protection only in the rrPorB in Ribi delivered by footpad vaccine regimen.
Frontiers in Microbiology | Cellular and Infection Microbiology June 2011 | Volume 2 | Article 124 | 6
Zhu et al. Vaccine for gonorrhea?
A 
Log10  
CFU 
1.0 
2.0 
3.0 
4.0 
5.0 
0 1 3 5 7 9 11 
Day post-inoculation 
B
Day post-inoculation 
0 
1.0 
2.0 
3.0 
4.0 
5.0 
1 3 5 7 9 11 
FIGURE 1 | Sialylation does not protect GC from OMV vaccine-induced
immune responses. Groups of BALB/c mice (n =10–12 per group)
were immunized with 20μg of OMV () from strain F62 via the IN,
subcutaneous, and IN routes separated by 3-week intervals or given PBS ()
by the same routes. Three weeks after the ﬁnal immunization, mice were
challenged vaginally with (A) wild-type F62 bacteria or the (B) F62
lst::aphA3 mutant (GP330). Vaginal mucus was cultured every other day
for 11 days. The average log10CFU per 100μl vaginal swab suspension
over time is shown with standard error bars. There was no difference in the
number of GC recovered (repeated measures ANOVA) or duration of
colonization (Log rank test) for any experimental group. This experiment was
repeated using three IN immunizations and another experiment was
performed with strain MS11 and an MS11 lst mutant, and the results were
similar.
of replication (VRP). One of these VRP systems, based on the
alphavirus Venezuelan encephalitis virus (VEE), provides both
systemic and mucosal immune responses, and is being used for
a variety of novel vaccines Davis et al., 1996; Hubby et al., 2007).
We prepared bothDNA andVEE-VRP vaccines for each of FA1090
TbpB and PorB (Zhu et al., 2004, 2005; Thomas et al., 2006).
The PorB-DNA vaccine appeared promising in terms of
immune responses (Zhu et al., 2004). PorB-DNA was particu-
larly immunogenic in BALB/c mice when boosted either by rrPorB
in Ribi-R700 adjuvant, or by PorB-VRP. Delivery of PorB-DNA
by the IM route resulted in a polarized Th1 response, but deliv-
ery by a gene gun to the epidermis, resulted in a predominantly
Th2 response (Zhu et al., 2004). Boosting with PorB-VRP drove
the response to a more dominant Th1 response. Serum antibod-
ies with opsonophagocytic activity against FA1090 were observed
after DNA immunization. Ability to control the direction of the
immune response might be useful for vaccine development in the
mouse, but because of the relatively greater immune responses
elicited by PorB-VRPs boosted by rrPorB (below), and by other
practical considerations, our vaccine efﬁcacy experiments were
limited to the PorB-VRP and rrPorB antigens.
Based on the ratio of PorB-speciﬁc IgG1/IgG2 antibody
responses, there was an apparent Th1 bias with either the PorB-
VRP vaccine, delivered without additional adjuvants into a rear
footpad (FP), or with the rrPorB vaccine delivered with Ribi-R700
adjuvant into a rear FP. In contrast, there was an apparent Th2 bias
when the rrPorB vaccinewith Ribi was delivered into the dorsal SQ
region. ELISPOTassays of harvested splenocytes showed that there
was a signiﬁcant interferon-γ (IFN-γ) response to PorB peptides
only after immunization with the PorB-VRP vaccine (Zhu et al.,
2005).Highest serum IgG responseswere observedwith the rrPorB
immunization, accompanied by vaginal mucosal IgG but not IgA
responses. The best mucosal IgG responses were observed after
rrPorB immunization, whereas the highest mucosal IgA responses
were after IN OMV immunization (Zhu et al., 2005).
MICE WERE PROTECTED BY A VRP VACCINE
Initial vaccination/protection experiments utilized rrPorB with
Ribi-R700 adjuvant. Delivery of the vaccine in the dorsal SQ
route resulted in no protection, but delivery into the FP resulted
in a weak, statistically insigniﬁcant, but repeatable trend toward
protection, manifest by about a 2-day reduction in colonization
(Table 1 and data not shown). We designed additional experi-
ments to test whether a prime-boost regimen utilizing the rrPorB
and PorB-VRP vaccinesmight yield improved results. Four groups
of 24 animals eachwere immunized three times at 2-week intervals
with either mock control, rrPorB-R700 in the FP× 3, PorB-VRP
in FP× 3, or PorB-VRP in FP× 2 plus a boost with rrPorB-R700
in FP (Figure 2). There was a trend toward reduced duration of
infection in the PorB-VRP in FP × 3 group (p = 0.11), and in sig-
niﬁcant protection (p < 0.01) in the PorB-VRP plus rrPorB-R700
boost group.
These results were encouraging, even though the vaccines
did not prevent infection. The experiment was repeated, adding
an additional control consisting of an irrelevant inﬂuenza virus
hemagglutinin antigen VRP construct (HA-VRP). Because the
most effective vaccine in the previous experiment was PorB-
VRP× 2 boosted with rrPorB, the control HA-VRP vaccine was
given twice, and boosted with rrPorB. This tested for the possible
effects of the VRP vector. The mock PBS control also was given
twice and boosted once with rrPorB, to control for the effects
of a single dose of rrPorB. The results (Figure 3) were interest-
ing. Both the PorB-VRP vaccine, boosted once with rrPorB, and
the HA-VRP vaccine boosted once with rrPorB resulted in sig-
niﬁcant (p < 0.05) reduction in duration of infection compared
to the PBS control boosted once with rrPorB. The single booster
dose of rrPorB given after PBS× 2 had no effect, compared to PBS
without rrPorB. There was no difference in colonization between
the HA-VRP× 2+ rrPorB boost and the PorB-VRP× 2+ rrPorB
boost vaccines. We tentatively concluded that the VRP vector was
the important component of the vaccine, and that PorB expressed
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FIGURE 2 | PorB-VRP×2 in FP plus boost with rrPorB in FP protects
against vaginal infection in the mouse model.Three- to four-week old
female BALB/c mice were divided randomly into four groups of 24 and
vaccinated three times at 2weeks interval. Mice were immunized with
three doses of PBS (, mock, n =8), rrPorB (, n =10), PorB-VRP (,
n =13) or 2 doses of PorB-VRP with 1 boost of rrPorB (◦, n =13). All doses
of immunogens, in a volume of 20μl, were given through the left footpad
after the animals had been anesthetized. Two weeks after the last boost,
mice in the diestrus phase were implanted with estradiol pellets and
treated with antibiotic. They were inoculated intravaginally with 1×106 CFU
of FA1090 2days later. Daily vaginal cultures were processed for total
recovery from the infection. Days to last positive culture are shown.
Log-rank test for equality to the Mock group yielded the following p values:
PorB-VRP+ rrPorB boost, p =<0.01; PorB-VRP without rrPorB boost,
p =0.11; rrPorB alone, p =0.40.
by the VRP vector might not be necessary for protection. Note
that infectious challenge was initiated 4weeks after the last dose of
PorB-VRP in the PorB-VRP× 2 plus rrPorB boost group, so the
effects of the VRP vector were durable.
How could a vector expressing an irrelevant peptide provide
protection against GC infection? Protection was not correlated
with serum PorB-speciﬁc IgG, since there was no more PorB IgG
in sera after immunization with the effective HA-VRP+ rrPorB
boost vaccine than the ineffective control PBS+ rrPorB boost vac-
cine (Figure 4). Serum levels of speciﬁc PorB IgG were at least
10-fold higher after immunization with the ineffective rrPorB× 3
vaccine (Zhu et al., 2005, and data not shown). Surface-bound
antibodies towholeGC alsoweremuch higher after the rrPorB × 3
in FP vaccine than after any of the VRP-based vaccines (data not
shown). Vaginal levels of PorB-speciﬁc IgA and IgG were much
higher after immunization with the ineffective rrPorB and OMV
vaccines than after the effective VRP-based vaccines (Zhu et al.,
2005). The only bactericidal antibody responses were observed
after the totally ineffective OMV vaccine. Thus, protection was
not correlated with measured antibody responses. Since we did
notmeasure speciﬁc IgG2b and IgG3 responses, conclusions about
the roles of isotypes in protection were not possible.
Although quantities of serum PorB-speciﬁc IgG were the same
in the ineffective PBS+ rrPorB boost group and the effective
HA-VRP+ rrPorB boost group (Figure 4), there could have
been unmeasured qualitative differences that accounted for the
observed differences in protection. Responses in Figure 4 were
FIGURE 3 | A PorB-VRP vaccine for gonorrhea in the mouse is no more
effective than a vaccine composed of the same vector expressing an
irrelevant peptide. BALB/c female mice were immunized in FP with either
PBS three times (, mock, n =17); PBS twice with a single boost of rrPorB
(,n =17); FA1090 PorB-VRP twice with a single boost of rrPorB (◦,n =18);
or inﬂuenza HA-VRP twice, also boosted once with rrPorB (•,n =18). The
rrPorB boosts consisted of 10μg of FA1090 rrPorB in 10μl PBS mixed 1:1
with Ribi-700 adjuvant. Immunizations were at 2-week intervals. The VRP
preparations were administered in a dose of about 1×106 particles without
additional adjuvant. The volume of all immunizations was 20μl. Two weeks
after the ﬁnal immunization, mice in diestrus were recruited for the
challenge with FA1090, as inTable 1. Days to last positive culture are
shown. Log rank was used to compare all four groups; results were
signiﬁcantly different among the groups (p =0.03). The only pairwise
comparisons which were signiﬁcantly different (p <0.05) were PBS alone
vs HA-VRP+ rrPorB (p =0.03), PBS+ rrPorB vs HA-VRP+ rrPorB (p =0.01),
and PBS+ rrPorB vs PorB-VRP+ rrPorB (p =0.04).
measured to synthetic peptides; PorB-conformation-speciﬁc anti-
bodies were not measured, nor were antibody avidities. Moreover,
there was a minimal serum IgG response to PorB peptides after
HA-VRP immunization× 2, without the rrPorB boost (520 ng/ml
PorB-reactive IgG as compared to 4135 ng/ml after PorB-VRP × 2
without rrrPorB boost, and no detectable response after immu-
nization with PBS× 2, data not shown). Therefore, the rrPorB
boost after the HA-VRP regimen could have resulted in a sec-
ondary immune response with different antibody characteristics
as compared to a primary immunization with rrPorB after immu-
nization with PBS. Reasons for the small serum IgG response to
HA-VRP are not understood; no linear amino acid (aa) sequence
identities longer than 4 aa were identiﬁed between FA1090 PorB,
and either HA, the VEE capsid protein, or the VEE surface glyco-
proteins E1, E2, or E3 (data not shown). Since experiments were
not conducted with an emptyVRP vector, the observed protection
could have had something to do with HA rather than the VRP
vector.
We considered that an IFN-γ Th1 response might be the
best correlate of protection, since PorB peptide-speciﬁc spenocyte
IFN-γ responses were signiﬁcantly greater after the VRP vaccines
than after either the rrPorB or OMV vaccines (Zhu et al., 2005).
However, the IFN-γ responses measured 4weeks after the immu-
nizations were completed, and 2weeks after infection, were iden-
tical in the ineffective rrPorB× 3 and the PorB-VRP× 2+ rrPorB
boost vaccines (Zhu et al., 2005, Figures 5A,B), suggesting that it
might not have been the IFN-γ responses per se, but something
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FIGURE 4 | PorB specific IgG levels in sera after different vaccination
regimens. BALB/c mice were immunized with HA-VRP, PorB-VRP, or PBS
for two times at 2weeks intervals and then boosted with rrPorB as the last
immunization. Another control group was immunized three times with PBS
at 2weeks intervals. Four weeks after the last immunization, sera were
collected and IgG responses against a pool of synthetic PorB peptides were
measured by quantitative ELISA. Each column represents mean±SD. Data
were analyzed by one-way ANOVA followed by unpaired Student’s t -test.
Symbols: **p <0.01; ***p <0.001 as compared to PBS control.
PBS+ rrPorB is different from PorB-VRP+ rrPorB (p =0.002);
PorB-VRP+ rrPorB is different from HA-VRP+ rrPorB (p =0.003); but
PBS+ rrPorB is not different from HA-VRP+ rrPorB (p =0.32).
else triggered after vaccination with the HA-VRP vaccine that
was most important. Although IFN-γ responses are important for
immune responses to antigens expressed by VRP vectors, they are
not important for the adjuvant effect of empty VRPs (Thompson
et al., 2008a).
WHAT IS SPECIAL ABOUT VRPs?
The VEE VRP system has been shown to stimulate a strong adju-
vant effect, especially when empty VRPs are delivered simultane-
ously with antigen (Thompson et al., 2006; Tonkin et al., 2010;
Carroll et al., 2011). The effect is at least as great as that driven by
other adjuvants such as CpG, and depends on VRP RNA replica-
tion (Thompson et al., 2006). Systemic and mucosal responses are
enhanced, involving both B and T cells; a robust antigen-speciﬁc
CD8+ T cell response is generated (Thompson et al., 2008b). The
effect does not depend on delivery of VRP into the mouse FP,
but is seen after IM injection as well (Tonkin et al., 2010). After
VRP delivery, dendritic cells as well as macrophages and NK cells
are stimulated to release a variety of cytokines and chemokines,
with increased cellularity in involved lymph nodes. The list of
cytokines and chemokines is interestingbothbywhat is stimulated,
and what is not: IL-12 and IL-17 are not stimulated, but IL-6, G-
CSF, GM-CSF, IFN-γ, MIP-2, and MCP-1 are stimulated (Tonkin
et al., 2010). We did not try to dissect the various components of
innate immune responses after the VRP immunizations, and did
not measure speciﬁc T cell responses. The purported effects of
the VRP vector could have been mediated by a variety of mecha-
nisms, including increased production of defensins or other innate
responses, or by conformation or avidity differences in antibodies
produced in the different vaccination regimens. Future explo-
ration of the basis of the apparent protective effects of VRP-based
immunization as a means to enhance GC vaccines should be a
fertile ﬁeld of study.
FUTURE DIRECTIONS
If there is to be a vaccine for GC, a renewed effort is needed in
several areas. First is in the search for correlates of immune pro-
tection in humans. It is not obvious how to accomplish this in the
absence of acquired immunity in humans. Oneway forwardmight
be a prospective examination of sexual partners of infected sub-
jects, inquiring as to the immune parameters (especial at mucosal
surfaces, including innate responses) in those who, and those who
do not, become infected. About two-thirds of exposed women
become infected; there may be differences in immune responses
at ﬁrst exposure, or a week after exposure, that would provide
leads. Similar studies in male volunteers are indicated as well;
about 50% of volunteers exposed to 1× 105 CFU of strain FA1090
develop urethral infection. Theremay be differences in early innate
responses in thosewho do, and thosewho donot, become infected.
The mouse model also offers opportunities, especially as new
transgenic mice become available, that express one or several
human gene products essential for GC infection. Transgenic mice
expressing receptors for Opa proteins including CEACAM1 (Gu
et al., 2010), human fH (Ufret-Vincenty et al., 2010), and transfer-
rin (Li et al., 2010) are available already.Humanizedmousemodels
are being generated in multiple laboratories (Zhang et al., 2007;
Denton and Garcia, 2009), and with further improvement, may
be helpful in assessing human-like immune responses in mice. A
mouse model that allowed substantial growth of the inoculum,
and longer persistence of infection, would assist in developing
correlates of protection in the mouse. Among other parameters,
mice can be monitored for the quality of the immune response
to experimental vaccines, focusing on generation of cells that are
positive for each of IL-2, IFN-γ, and TNF. Substantial experience
shows that such T cell responses are correlated with a variety of
effective vaccines (Seder et al., 2008).
There are multiple candidate proteins that can be consid-
ered for a subunit vaccine, with or without lipid A-detoxiﬁed
OMVs. These include PorB, which remains attractive even though
extensive studies cited above have not been fruitful. An approach
aimed speciﬁcally at PorB loop domains involved in binding fH,
C4bp, and/or host receptor binding to CR3 might yield better
results than whole PorB. Such a directed response might block
binding to and invasion of host cells, and could be bactericidal
either directly, or by blocking fH or C4b binding. One way to
do this is being explored by one of us (Ann E. Jerse), utilizing
circular loop peptides as the immmunogens, based on evidence
that analagous circular Opa peptides are able to elicit potentially
protective immune responses (Cole and Jerse, 2009). Intranasal
immunization with the GC transferrin-binding proteins TbpA
or TbpB, or both, elicited bactericidal immune responses; TbpA
stimulated more broadly cross-reactive antibodies than did TbpB
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(Price et al., 2005). Immunization of mice with genetic chimeras
that fused parts of TbpA and TbpB stimulated production of vagi-
nal antibodies that inhibited growth in vitro (Price et al., 2007). A
novel adhesin designated OmpA is yet another candidate (Serino
et al., 2007).
Extensive studies over thepast 15 years have shown thepotential
of vaccines directed at a conserved LOS epitope, which is deﬁned
by binding the mAb 2C7 (Gulati et al., 1996). About 95% of GC
strains express the 2C7 epitope, composed principally of a lactose
residue attached to heptose-2 on GC LOS (Yamasaki et al., 1999).
Synthetic peptides that mimic the 2C7 epitope are immunogenic,
and result in bactericidal activity, even against strains that are resis-
tant to killing by normal human serum (Ngampasutadol et al.,
2006).
There may be other effective immunogens. Perhaps improved
mouse models will permit a discovery approach that utilizes
pools of antigens, delivered as DNA constructs. Priming with
VRP-based vaccines, or a variety of other novel adjuvants (Gwinn
et al., 2010; Pulendran et al., 2010), may enable more effective
immune responses. The pace of discovery in mucosal immunol-
ogy is rapid; efforts to develop more effective genital immune
responses, including nasal immunization strategies (Gwinn et al.,
2010),may pay dividends. Progress will require a substantial com-
mitment of effort and resources. It is not too early to renew the
effort.
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